Dr Vladislav Sandler, Co-Founder and CEO of HemoGenyx Pharmaceuticals #LSE #HEMO discusses two major announcements with London South East.

1. First data results show that CDX antibodies have been successfully tested on real AML Leukemia cells. Dr Sandlar said he was 'ecstatic' when the results came through. These tests are specific to the blood cancer Acute Myelogenous Leukemia (AML) in vitro.
2. HemoGenyx have been working with a new type of 'humanised mice' in these trials and have made a Patent application. These mice allow researchers to test and develop drugs in a much more efficient and fast way, in a live animal on a 'human background' using human cells which live inside that animal.

Dr Sandler hopes other organisations might use them for product development, other disease modelling and drug development and is in discussions with several organisations.